Electric dipole moment of 13^{13}C

We calculate for the first time the electric dipole moment (EDM) of $^{13}$C generated by the isovector CP-odd pion exchange nuclear force in the $\alpha$-cluster model, which describes well the structures of low lying states of the $^{13}$C nucleus. The linear dependence of the EDM of $^{13}$C on the neutron EDM and the isovector CP-odd nuclear coupling is found to be $d_{^{13}{\rm C}} = -0.33 d_n - 0.0020 \bar G_\pi^{(1)}$. The linear enhancement factor of the CP-odd nuclear coupling is smaller than that of the deuteron, due to the difference of the structure between the $1/2^-_1$ state and the opposite parity ($1/2^+$) states. We clarify the role of the structure played in the enhancement of the EDM. This result provides good guiding principles to search for other nuclei with large enhancement factor. We also mention the role of the EDM of $^{13}$C in determining the new physics beyond the standard model.Comment: 11 pages, 4 figure

Alpha-clustered hypernuclei and chiral SU(3) dynamics

Light hypernuclei with an $\alpha$ cluster substructure of the core nucleus are studied using an accurate cluster approach (the Hyper-THSR wave function) in combination with a density-dependent $\Lambda$ hyperon-nuclear interaction derived from chiral SU(3) effective field theory. This interaction includes important two-pion exchange processes involving $\Sigma N$ intermediate states and associated three-body mechanisms as well as effective mass and surface terms arising in a derivative expansion of the in-medium $\Lambda$ self-energy. Applications and calculated results are presented and discussed for $_\Lambda^9$Be and $^{13}_\Lambda$C. Furthermore, the result of the lightest $\alpha$ clustered hypernucleus, $^5_{\Lambda}$He using realistic $ab initio$ four nucleon density is shown.Comment: To be submitted in PTE

Rapidly Growing Esophageal Carcinosarcoma Reduced by Neoadjuvant Radiotherapy Alone

Esophageal carcinosarcoma is a rare malignant neoplasm consisting of both carcinomatous and sarcomatous components. It is generally treated by surgery, radiotherapy and chemotherapy according to the protocols used for other esophageal cancers. However, the treatment of esophageal carcinosarcoma by radiotherapy alone before surgery has not been previously described. We report a patient with a rapidly growing esophageal carcinosarcoma that was efficiently reduced by neoadjuvant radiotherapy alone. A previously healthy 69-year-old man was admitted with dysphagia. Initial esophagogastroduodenoscopy (EGD) revealed a small nodular polypoid lesion of about 10 mm in the middle esophagus. A second EGD 1 month later showed that the tumor had expanded into a huge mass. A biopsy specimen revealed that the tumor comprised squamous cell carcinoma with spindle cell components, and the tumor was diagnosed as carcinosarcoma which was diagnosed as stage I (T1bN0M0). Due to renal dysfunction, the patient was treated with neoadjuvant radiotherapy (40 Gy) without chemotherapy. A third EGD 1 month later revealed remarkable tumor reduction. He then underwent total esophagectomy with regional lymph node dissection (pStage 0, pT1aN0M0). After surgical operation, the patient was followed up without adjuvant therapy. Whole body computed tomography revealed lung metastasis 14 months after surgery, and the patient died 2 months later. The neoadjuvant radiotherapy for esophageal carcinosarcoma was considered to have contributed to the subsequent surgery and his prolonged survival time. Thus, radiotherapy alone might be a suitable neoadjuvant therapy for esophageal carcinosarcomas

Prolonged Survival in a Case of Chemotherapy-Sensitive Gastric Cancer That Produced Alpha-Fetoprotein and Protein Induced by Vitamin K Antagonist-II

The number of reported cases of alpha-fetoprotein (AFP)-producing gastric cancer has gradually increased, with a reported prevalence of 1.3-1.5% of all gastric cancer cases. However, reports of gastric cancer accompanied by elevated serum levels of both AFP and protein induced by vitamin K antagonist-II (PIVKA-II) are rare. The prognosis of AFP- and PIVKA-II-producing gastric cancer has been reported to be very poor because the tumor cells were considered to have a high malignant potential and the cancer progressed rapidly. We described a case of gastric cancer producing AFP and PIVKA-II in which chemotherapy was effective and resulted in prolonged survival, and these two tumor markers were useful for monitoring the treatment response. Routine health screening using upper abdominal ultrasonography revealed hepatic tumors in an apparently healthy 65-year-old man. Whole-body computed tomography (CT) revealed multiple hepatic tumors, and an esophagogastroduodenoscopy (EGD) revealed a Bormann type 3 tumor in the lower stomach. A biopsy specimen confirmed that the tumor was immunohistochemically positive for AFP, PIVKA-II, and human epidermal growth factor receptor 2. After chemotherapy, the gastric tumor appeared as a small elevated lesion on EGD, and CT revealed a remarkable reduction in the size of the metastatic liver tumors. The patient is still alive, 35 months after the initial chemotherapy